Agile Therapeutics, Inc. (NASDAQ:AGRX) Receives $3.63 Average Target Price from Brokerages

Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) have received an average recommendation of “Buy” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $3.63.

AGRX has been the topic of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $1.03 price target (down from $6.00) on shares of Agile Therapeutics in a research report on Tuesday, July 27th. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of Agile Therapeutics in a research report on Friday, August 20th. HC Wainwright reduced their price target on Agile Therapeutics from $7.00 to $3.50 and set a “buy” rating on the stock in a research report on Monday, September 13th. Finally, Zacks Investment Research upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 21st.

In other news, CFO Dennis Reilly purchased 50,000 shares of the stock in a transaction dated Tuesday, July 27th. The stock was acquired at an average cost of $1.08 per share, for a total transaction of $54,000.00. Following the acquisition, the chief financial officer now owns 226,306 shares of the company’s stock, valued at $244,410.48. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Alfred Altomari purchased 26,200 shares of the stock in a transaction dated Thursday, July 29th. The stock was purchased at an average price of $1.26 per share, with a total value of $33,012.00. The disclosure for this purchase can be found here. 8.50% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Agile Therapeutics during the 2nd quarter worth $2,000,000. Geode Capital Management LLC grew its stake in Agile Therapeutics by 12.2% during the 1st quarter. Geode Capital Management LLC now owns 1,237,241 shares of the specialty pharmaceutical company’s stock worth $2,573,000 after buying an additional 134,999 shares during the last quarter. Royal Bank of Canada grew its stake in Agile Therapeutics by 6.5% during the 2nd quarter. Royal Bank of Canada now owns 994,071 shares of the specialty pharmaceutical company’s stock worth $1,322,000 after buying an additional 60,835 shares during the last quarter. Renaissance Technologies LLC boosted its position in Agile Therapeutics by 117.8% during the 2nd quarter. Renaissance Technologies LLC now owns 835,559 shares of the specialty pharmaceutical company’s stock worth $1,111,000 after acquiring an additional 451,948 shares during the period. Finally, Morgan Stanley boosted its position in Agile Therapeutics by 3,348.3% during the 2nd quarter. Morgan Stanley now owns 769,445 shares of the specialty pharmaceutical company’s stock worth $1,023,000 after acquiring an additional 747,131 shares during the period. Hedge funds and other institutional investors own 36.84% of the company’s stock.

Shares of NASDAQ AGRX remained flat at $$1.03 during midday trading on Friday. The stock had a trading volume of 328,196 shares, compared to its average volume of 510,536. Agile Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $3.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.18 and a quick ratio of 2.88. The business has a fifty day moving average of $1.11 and a two-hundred day moving average of $1.48.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Sunday, July 25th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.45 million. On average, equities research analysts expect that Agile Therapeutics will post -0.78 EPS for the current fiscal year.

About Agile Therapeutics

Agile Therapeutics, Inc is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More: What are the FAANG Stocks?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.